Vimarsana
Biggest News Aggregation in the World

Acesion Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acesion Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acesion Pharma Today - Breaking & Trending Today

The 9 best biotech companies in Denmark - Vimarsana News

The 9 best biotech companies in Denmark

Discover Denmark's dynamic biotech scene with 9 innovative companies at the forefront of the biopharmaceutical revolution!

Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion) - Vimarsana News

Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)

/PRNewswire/ -- Novo Holdings today announced its financial results for 2023*. Strong Investment Portfolio performance, and growth of the Novo Group companies...

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation - Vimarsana News

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation

/PRNewswire/ -- Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ("AF"), the...

15 Countries with the Highest Number of Heart Diseases - Vimarsana News

15 Countries with the Highest Number of Heart Diseases

In this article, we will be taking a look at the 15 countries with the highest number of heart diseases.

Avalyn's New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials - Vimarsana News

Avalyn's New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials

Avalyn Pharma aims to improve treatment of Idiopathic pulmonary fibrosis with inhalable versions of two older oral drugs and it’s now headed for mid-stage testing backed by a Series C financing. Other recent biotech industry financings raised money for research in cancer, immunology, and rare genetic diseases.